{"id":"W3135190823","doi":"10.1177/1756286420987941","title":"Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"AbbVie Biotherapeutics; Biogen","keywords":"Medicine; Daclizumab; Multiple sclerosis; BETA (programming language); Relapsing remitting; Internal medicine; Oncology; Immunology; Monoclonal antibody; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005132228,0.0002226313,0.0006221178,0.0001992344,0.00008014643,0.00002669116,0.0002072841,0.00007653339,0.000004990526],"category_scores_gemma":[0.001087745,0.0001710613,0.00003508268,0.0007863368,0.0002125571,0.0003378592,0.0003138225,0.0004634106,5.666058e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004588732,"about_ca_system_score_gemma":0.00004076344,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008701748,"about_ca_topic_score_gemma":0.001192809,"domain_scores_codex":[0.9973274,0.0004928333,0.000628944,0.0006707203,0.0004739474,0.0004061366],"domain_scores_gemma":[0.9983788,0.001051314,0.0001343662,0.0003087583,0.00006472931,0.00006203094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01477425,0.004958198,0.8391606,0.00002774338,0.00002998978,0.00003297903,0.0009295724,0.0001583363,0.0001220467,0.00001187384,2.316247e-7,0.1397942],"study_design_scores_gemma":[0.06697048,0.003624896,0.9277015,0.0002797577,0.00002461019,4.313088e-7,0.0004721851,0.0006366945,0.00001178955,0.00009434193,0.00003575837,0.0001475112],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964972,0.0009578342,0.00002906365,0.0004416948,0.00004134967,0.001724281,0.00001187528,0.00001575357,0.0002810019],"genre_scores_gemma":[0.9974269,0.001773081,0.0005830571,0.0001035776,0.000004961255,0.0000610205,0.00001713769,0.00002014396,0.00001014883],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1396466,"threshold_uncertainty_score":0.6975679,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06762489834413932,"score_gpt":0.341432496039235,"score_spread":0.2738075976950957,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}